SCHEMBL14803773

SCHEMBL14803773

CC(=O)Nc1cnccc1C(C)(C)C

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ KDM4C Q9H3R0 2/20 0.41
▸ CHUK O15111 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ SLC22A12 Q96S37 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26624210 0.85 GAA (0.57) GAAALDH1A1KDM4CCHUKMAPT
SCHEMBL13748300 0.81 NAMPT (0.47) GAARAB9A
SCHEMBL10338664 0.80 KDM4C (0.47) GAAALDH1A1KDM4CCHUKMAPT
SCHEMBL12341052 0.77 MEN1 (0.42) GAAALDH1A1TDP1KDM4CMAPT
SCHEMBL1637363 0.77 ALDH1A1 (0.55) ALDH1A1TDP1KDM4CCHUKMAPT
SCHEMBL30418934 0.77 ALDH1A1 (0.55) ALDH1A1TDP1KDM4CCHUKMAPT
SCHEMBL3194739 0.77 MAPT (0.47) GAAALDH1A1KDM4CCHUKMAPT
SCHEMBL14803886 0.75 POLB (0.50) ALDH1A1KDM4CMAPTSMN1; SMN2HTT
SCHEMBL14357917 0.75 HDAC1 (0.46) GAAALDH1A1TDP1KDM4CCHUK
SCHEMBL29870952 0.75 KDM4C (0.43) ALDH1A1KDM4CCHUKMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169246-B2 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2015-10-27 — — US disclosed
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-21 — — US disclosed
US-20130079337-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079337-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CYP11B2, COQ8A, CYP1A2 GAA 1467/4885ALDH1A1 88/4885TDP1 801/4885
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CYP11B2, CYP1A2, COQ8A GAA 1631/4885ALDH1A1 97/4885TDP1 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback